A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254 Academic Article uri icon


MeSH Major

  • Adjuvants, Immunologic
  • Bone Marrow Transplantation
  • Immunoconjugates
  • Lymphoma, B-Cell
  • Ricin
  • Transplantation, Autologous


  • Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively (p = 0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively (p = 0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma.

publication date

  • April 2011



  • Academic Article



  • eng

PubMed Central ID

  • PMC3682835

Digital Object Identifier (DOI)

  • 10.3109/10428194.2010.543714

PubMed ID

  • 21275630

Additional Document Info

start page

  • 587

end page

  • 96


  • 52


  • 4